Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871963 | 0.93 | SIGMAR1 (0.79) | SIGMAR1ALDH1A1KDM4EDRD2DRD3 | |
| SCHEMBL4870310 | 0.81 | SIGMAR1 (1.00) | SIGMAR1ALDH1A1DRD2DRD3POLB | |
| SCHEMBL4870315 | 0.81 | SIGMAR1 (1.00) | SIGMAR1ALDH1A1DRD2DRD3POLB | |
| SCHEMBL4867118 | 0.80 | SIGMAR1 (0.97) | SIGMAR1DRD2DRD3POLB | |
| SCHEMBL5180920 | 0.77 | SIGMAR1 (0.80) | SIGMAR1ALDH1A1DRD2DRD3POLB | |
| SCHEMBL5180929 | 0.77 | SIGMAR1 (0.80) | SIGMAR1ALDH1A1DRD2DRD3POLB | |
| SCHEMBL4876861 | 0.77 | SIGMAR1 (1.00) | SIGMAR1DRD2DRD3POLBCYP2D6 | |
| SCHEMBL4876867 | 0.77 | SIGMAR1 (1.00) | SIGMAR1DRD2DRD3POLBCYP2D6 | |
| SCHEMBL4874862 | 0.77 | SIGMAR1 (1.00) | SIGMAR1ALDH1A1SMN1; SMN2KDM4EDRD2 | |
| SCHEMBL4874859 | 0.77 | SIGMAR1 (1.00) | SIGMAR1ALDH1A1SMN1; SMN2KDM4EDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153917-A1 | Sigma Receptor Ligands | UCB PHARMA, S.A. (BE) | 2008-06-26 | — | — | US | claimed |
| EP-1797036-A1 | SIGMA RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006027252-A1 | SIGMA RECEPTOR LIGANDS | UCB PHARMA, SA (BE) | 2006-03-16 | — | — | WO | claimed |
| US-20080153917-A1 | Sigma Receptor Ligands | UCB PHARMA, S.A. (BE) | 2008-06-26 | — | — | US | disclosed |
| EP-1797036-A1 | SIGMA RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006027252-A1 | SIGMA RECEPTOR LIGANDS | UCB PHARMA, SA (BE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153917-A1 | Sigma Receptor Ligands | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885ALDH1A1 2385/4885SMN1; SMN2 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.